Artwork

Content provided by David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

30: From Monoclonals to Gene Therapy: Tips for Process Development w/ Neil Templeton - Part 2

14:56
 
Distribuie
 

Manage episode 402348255 series 3525243
Content provided by David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

In our insightful second part of the conversation, we broaden our perspective to delve into the various modalities within the biotech industry, highlighting the unique and shared aspects of process development and scale-up.

Neil Templeton, the Director of Upstream Process Development at Solid Biosciences, passionately articulates his commitment towards making gene therapy more accessible. He does this by outlining strategic solutions to reduce the costs of development and manufacturing.

You will gain:

  1. A comprehensive understanding of process development's similarities and differences across biologics, vaccines, and cell and gene therapy manufacturing.
  2. Effective strategies aimed at reducing the costs associated with gene therapy development and manufacturing.
  3. Insights into how capitalizing on the expertise from the biologics sector can positively impact other fields.

To connect with Neil Templeton and learn more about his work, visit his LinkedIn profile.

LinkedIn: https://www.linkedin.com/in/neil-templeton
Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

  continue reading

55 episoade

Artwork
iconDistribuie
 
Manage episode 402348255 series 3525243
Content provided by David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

In our insightful second part of the conversation, we broaden our perspective to delve into the various modalities within the biotech industry, highlighting the unique and shared aspects of process development and scale-up.

Neil Templeton, the Director of Upstream Process Development at Solid Biosciences, passionately articulates his commitment towards making gene therapy more accessible. He does this by outlining strategic solutions to reduce the costs of development and manufacturing.

You will gain:

  1. A comprehensive understanding of process development's similarities and differences across biologics, vaccines, and cell and gene therapy manufacturing.
  2. Effective strategies aimed at reducing the costs associated with gene therapy development and manufacturing.
  3. Insights into how capitalizing on the expertise from the biologics sector can positively impact other fields.

To connect with Neil Templeton and learn more about his work, visit his LinkedIn profile.

LinkedIn: https://www.linkedin.com/in/neil-templeton
Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

  continue reading

55 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință